Company intelligence / Profile preview

Zoono

Auckland, New Zealand

Ownership: Private
Development stage: Other

Overview

Zoono's technology, based on a patented 'Zoono molecule', is in commercial use as sprays, wipes, and foams for surface and skin disinfection, with independent laboratory validation demonstrating efficacy against bacteria, viruses, fungi, algae, and mould. The company markets globally and is available in public health, consumer, corporate, education, and healthcare sectors; products have regulatory approvals in various regions.

Therapeutic areas: Infectious DiseasesDermatology
Modalities: DeviceSurface coatingBiologic
Industry: Consumable Medical Devices

Partnerships

Major partnerships in public transport, education, corporate, and healthcare sectors

Beyond the preview

Go deeper on Zoono.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zoono.

Explore the full profile